recent
year
incid
west
nile
viru
wnv
infect
culex
human
increas
greatli
due
global
travel
rais
public
health
concern
wnv
pandem
north
america
could
recur
vaccin
treatment
develop
includ
imino
sugar
deriv
dna
vaccin
interferon
treatment
human
monoclon
antibodi
clinic
evalu
mab
therapeut
flaviviru
infect
monitor
select
emerg
resist
variant
especi
immunocompromis
patient
like
target
popul
treatment
sever
wnv
infect
use
larg
dose
ribavirin
inhibit
wnv
replic
vitro
howev
less
effici
mortal
hamster
infect
wnv
increas
ribavirin
inject
wnv
rna
replic
process
inhibit
vitro
mycophenol
anoth
candid
inhibitor
show
protect
effect
vivo
anoth
clinic
studi
indic
interferon
alpha
could
protect
wnv
infect
howev
limit
evid
shown
could
cure
patient
seriou
wnv
enceph
sever
wnv
vaccin
recent
develop
includ
inactiv
subunit
live
attenu
vaccin
howev
vaccin
immun
might
protect
patient
alreadi
develop
wnv
neuroinvas
licens
vaccin
therapeut
human
use
studi
engl
diamond
found
immun
mous
antibodi
directli
use
human
due
heterogen
intact
mous
igg
risk
induc
allerg
respons
human
human
igg
readili
avail
larg
quantiti
passiv
immunotherapi
proven
use
mani
infecti
diseas
administr
polyclon
immunoglobulin
hyperimmun
anim
human
control
hepat
b
viru
hbv
human
immunodefici
viru
hiv
equin
f
fragment
reduc
polyclon
easi
purifi
larg
quantiti
rel
inexpens
success
use
prevent
rabi
viru
infect
snake
venom
human
serv
use
prepared
wnv
pandem
prepar
serum
igg
hors
immun
wnv
viruslik
particl
vlp
avoid
potenti
allerg
respons
pepsin
use
digest
antibodi
gener
f
fragment
protect
efficaci
serum
igg
f
fragment
wnv
evalu
vitro
vivo
serum
igg
f
fragment
neutral
wnv
infect
tissu
cultur
determin
plaqu
reduct
assay
furthermor
prophylact
therapeut
treatment
mice
purifi
igg
f
fragment
significantli
decreas
viral
load
spleen
brain
wnvinfect
mice
reduc
mortal
result
indic
equin
immunoglobulin
equin
neutral
f
passiv
immunotherapi
could
potenti
use
treatment
patient
infect
wnv
cell
infect
recombin
baculovirus
coexpress
wnv
structur
protein
e
multipl
infect
moi
cultur
supernat
harvest
h
post
infect
centrifug
rpm
min
remov
cell
debri
supernat
ultracentrifug
rpm
h
vlp
pellet
resuspend
phosphatebuff
salin
pb
load
discontinu
sucros
gradient
h
ultracentrifug
rpm
wnvvlpcontain
band
sucros
collect
two
healthi
brown
hors
kg
weight
detect
antibodi
wnv
provid
militari
hongshan
stud
farm
changchun
china
intramuscularli
multipoint
inject
submandibular
region
backsid
mg
wnvvlp
freund
adjuv
completeincomplet
sigma
st
loui
mo
usa
day
time
respect
sera
collect
jugular
vein
week
immun
store
analysi
wnvspecif
antibodi
serum
measur
indirect
enzymelink
immunosorb
assay
elisa
use
purifi
wnv
ediii
structur
domain
iii
e
protein
microtit
plate
corn
costar
cat
corn
ny
usa
use
elisa
eiaria
stripwel
plate
featur
polystyren
microtit
plate
flat
bottom
certifi
high
capac
bind
protein
briefli
microtit
plate
precoat
purifi
ediii
antigen
dilut
moll
carbon
sodium
buffer
ph
final
concentr
incub
overnight
block
skim
milk
h
twofold
serial
dilut
serum
sampl
ad
well
incub
h
plate
wash
three
time
pb
contain
pbst
hrp
horseradish
peroxidas
label
goat
antibodi
hors
igg
bio
china
ad
dilut
plate
incub
h
wash
pbst
substrat
tetramethyl
benzidin
tmb
sigma
ad
well
incub
min
reaction
stop
ad
optic
densiti
od
valu
measur
use
elisa
plate
reader
wavelength
nm
biorad
lo
angel
ca
usa
titer
result
indic
reciproc
serum
maximum
dilut
multipl
ratio
posit
od
valu
neg
od
valu
hors
antiwnv
serum
dilut
equal
volum
salin
volum
satur
ammonium
sulfat
solut
ad
solut
mix
gentli
room
temperatur
min
centrifug
rpm
min
precipit
dissolv
salin
volum
ammonium
sulfat
ad
incub
room
temperatur
min
solut
centrifug
rpm
min
precipit
dissolv
salin
dialyz
overnight
remov
salt
ph
hors
antiwnv
serum
adjust
moll
hcl
pepsin
activ
naac
solut
ph
ad
dilut
hors
antiserum
digest
h
reaction
stop
adjust
ph
moll
naoh
solut
appli
proteina
column
follow
prote
column
purifi
protein
subject
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
follow
coomassi
blue
stain
f
puriti
analyz
thin
slice
scan
protein
store
use
mice
background
initi
obtain
gener
gift
akira
osaka
univers
osaka
japan
purchas
charl
river
laboratori
mice
maintain
specificpathogenfre
anim
care
facil
univers
iowa
protocol
approv
univers
iowa
institut
anim
care
use
committe
wnv
strain
tx
wnvtx
propag
previous
describ
work
stock
wnvtx
gener
singl
round
amplif
vero
cell
titer
viru
stock
determin
standard
plaqu
assay
use
vero
cell
previous
describ
vero
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
work
wnv
conduct
univers
iowa
biosafeti
level
bsl
laboratori
serum
sampl
purifi
igg
f
serial
dilut
dmem
mix
pfu
plaqu
form
unit
wnv
incub
h
mixtur
ad
vero
cell
plate
incub
addit
h
absorpt
cell
overlaid
agaros
incub
day
agaros
plug
remov
plaqu
visual
crystal
violet
contain
ethanol
methanol
stain
eight
wild
type
mice
mice
treat
purifi
hors
immun
igg
purifi
hors
immun
f
via
intraperiton
ip
rout
one
day
andor
subcutan
sc
footpad
infect
pfu
wnv
mice
monitor
morbid
mortal
daili
spleen
brain
harvest
indic
time
point
titer
use
vero
cell
wnvvlp
produc
purifi
previous
describ
healthi
hors
intramuscularli
immun
wnvvlp
freund
adjuv
boost
everi
week
cycl
serial
serum
sampl
collect
igg
titer
wnv
ediii
measur
elisa
figur
ediiispecif
igg
titer
serum
five
immun
figur
immunoglobulin
precipit
use
satur
ammonium
sulfat
digest
pepsin
f
fragment
purifi
proteinag
chromatographi
integr
igg
f
fragment
evalu
use
sdspage
figur
puriti
f
fragment
proteinag
chromatographi
higher
figur
use
plaqu
reductionneutr
assay
confirm
immun
sera
effici
neutral
wnv
infect
vitro
half
effect
maxim
dilut
serum
serum
figur
b
furthermor
found
purifi
equin
igg
f
also
neutral
wnv
infect
half
effect
maxim
concentr
igg
f
fragment
respect
figur
note
f
fragment
lower
igg
vitro
result
suggest
equin
antibodi
product
exhibit
highli
potent
neutral
activ
wnv
tissu
cultur
valid
protect
effect
equin
antibodi
vivo
transfer
purifi
hors
immun
igg
purifi
hors
immun
f
intraperiton
mice
one
day
infect
day
wnv
infect
wild
type
wt
mice
receiv
immun
igg
f
surviv
wherea
wt
mice
receiv
control
hors
igg
die
regardless
whether
antibodi
administ
infect
mitochondri
antiviralsign
protein
mav
key
adaptor
molecul
rig
retino
acidinduc
gene
ilik
receptor
rnasens
pathway
mice
highli
suscept
uniformli
succumb
wnv
infect
death
occur
day
figur
howev
mice
receiv
hors
igg
one
day
infect
surviv
contrast
vitro
neutral
assay
figur
mice
receiv
f
fragment
show
delay
mortal
howev
mice
die
within
day
figur
immun
antibodi
transfer
one
day
infect
protect
mice
figur
furthermor
determin
whether
two
dose
equin
antibodi
treatment
could
enhanc
prophylact
function
mice
treat
mice
one
day
one
day
wnv
infect
mice
control
group
die
wherea
mice
receiv
hors
immun
igg
surviv
f
treatment
protect
mice
next
ask
whether
passiv
transfer
equin
immun
antibodi
could
decreas
wnv
load
vivo
wt
mice
infect
wnv
indic
time
point
spleen
brain
harvest
titer
expect
antibodi
treatment
decreas
viru
load
wt
mice
figur
previou
studi
shown
wnv
spread
air
transport
migrat
bird
current
wnv
circul
north
america
also
russia
india
australia
effect
treatment
licens
vaccin
exist
proven
human
use
studi
demonstr
ediiispecif
igg
titer
serum
five
immun
also
verifi
puriti
f
fragment
proteinag
chromatographi
higher
found
equin
antibodi
product
exhibit
highli
potent
neutral
activ
wnv
tissu
cultur
importantli
confirm
equin
antiwnv
immunoglobulin
neutral
f
decreas
viru
load
protect
mice
lethal
wnv
infect
use
mice
mice
background
studi
mice
immunocompet
broadli
use
wnv
studi
mortal
rate
around
mice
immunocompromis
defici
mav
gene
import
viral
rna
sens
mice
uniformli
succumb
wnv
infect
model
perfectli
mimic
wnv
infect
human
human
infect
infect
patient
intact
immun
system
get
mild
diseas
immunocompromis
patient
elderli
tend
develop
sever
neuroinvas
wnvvlp
use
immun
healthi
hors
gener
equin
antiwnv
igg
f
result
show
technic
feasibl
rapidli
gener
larg
amount
equin
neutral
antibodi
wnv
f
fragment
help
allevi
immun
hypersensit
make
antibodi
safer
human
use
importantli
equin
antiwnv
antibodi
polyclon
recogn
antigen
determin
wnv
glycoprotein
membran
monoclon
antibodi
could
potenti
avoid
antibodi
escap
highli
purifi
equin
f
fragment
shown
safe
human
use
treat
mani
diseas
decad
equin
f
fragment
surmount
bottleneck
antibodi
yield
possess
broader
antigen
coverag
avoid
emerg
escap
mutant
note
equin
antibodi
rel
econom
readili
avail
although
convalesc
plasma
patient
shown
protect
efficaci
neutral
antibodi
titer
patient
gener
low
limit
number
survivor
make
approach
impract
qualiti
neutral
antibodi
influenc
treatment
efficaci
may
depend
quantiti
qualiti
f
fragment
accord
assay
puriti
f
fragment
met
requir
bioprepar
china
result
studi
show
f
fragment
effici
igg
vitro
vivo
possibl
factor
contribut
outcom
f
shorter
halflif
igg
summari
immun
healthi
hors
wnvvlp
success
develop
first
equin
iggderiv
f
fragment
could
neutral
wnv
vitro
vivo
prophylact
therapeut
treatment
equin
antiwnv
immunoglobulin
neutral
f
decreas
viral
load
spleen
brain
protect
mice
lethal
wnv
infect
therefor
hors
immun
wnvvlp
could
serv
use
initi
sourc
develop
protect
f
fragment
may
use
prepared
serv
strateg
reserv
potenti
wnv
epidem
emerg
pathogen
success
develop
first
equin
iggderiv
f
fragment
could
neutral
wnv
vitro
vivo
prophylact
therapeut
treatment
equin
antiwnv
immunoglobulin
neutral
f
decreas
viral
load
spleen
brain
protect
mice
lethal
wnv
infect
result
indic
equin
immunoglobulin
equin
neutral
f
passiv
immunotherapi
could
potenti
use
treatment
patient
infect
wnv
